Freedman Joseph David

Director Freedman purchases 1,000 shares of BLNE at $1.85; 90d track record at BLNE shows 2 of 2 prior buys well-timed (+112.0%, +412.8%).

Director Joseph David Freedman purchased 1,000 shares at $1.85 on 2025-11-26, increasing his holdings by 0.3% to 364.9K shares. The stock has since declined 29.8% over 30 days and is trading at $2.05, -78.4% from its 52-week high of $9.50. Critically, Freedman's same-ticker purchase history shows a strong execution pattern: his two prior measurable buys at BLNE (on 2025-06-17) both delivered +112.0% 30-day returns and +412.8% 90-day returns, with both well-timed at the 90-day mark. However, this transaction is part of a rapid accumulation: Freedman also bought on 2025-11-21 and 2025-11-19, yet a September 2025 buy at BLNE posted a -20.8% 30-day return. The company posted $-3.9M net income on $2.3M quarterly revenue (negative full-year profitability) and flat annual revenue growth (-0.4%), creating structural headwinds. The recent 29.8% decline in 30 days and prior BLNE purchase underperformance suggest current market conditions diverge sharply from the favorable environment that produced the June 2025 buys.

Director Freedman purchases 3,000 BLNE shares at $1.46; stock down -48.2% in 30 days, yet insider's same-ticker history shows 3-for-3 well-timed prior buys.

Joseph David Freedman, a Director, purchased 3,000 shares of Beeline Holdings at $1.46 on 2025-11-21, the second open-market buy in three days and one of five tracked transactions at BLNE. The current price of $1.73 sits -81.8% from the 52-week high of $9.50 and has fallen -48.2% over the past 30 days, indicating severe recent weakness. However, his same-ticker history at BLNE reveals a meaningful pattern: all three prior buys with 90-day outcomes were well-timed (30-day returns of +112.0% and +113.6%, with 90-day returns of +412.8% and +416.7%), suggesting his prior entry points captured subsequent rallies despite buying into depressed conditions. Fundamentals remain challenged—the company reported a net loss of $3.9M against quarterly revenue of $2.3M and has negative annual revenue growth of -0.4%—yet the director's cross-ticker track record shows 17 prior open-market buys with an 86.67% 90-day win rate and an average 90-day return of +239.7%, indicating a consistent pattern of identifying entry points before recovery.

Director Freedman buys 7,000 shares of BLNE at $1.62; stock down -84.1% from 52-week high; company reporting $-3.9M net loss.

Director Joseph David Freedman purchased 7,000 shares at $1.62 on 2025-11-19, expanding his stake to 360.9K shares (+2.0%). The buy occurred in a heavily depressed price environment: BLNE trades at $1.51 against a 52-week high of $9.50 (-84.1%) and has fallen 55.1% in 30 days. Fundamentals remain challenged with quarterly revenue of $2.3M and a net loss of $-3.9M, though his prior four buys at BLNE were well-timed at the 90-day mark, with three trades in June 2025 posting +409% to +417% returns. His current purchase at an extreme low point, paired with his demonstrated ability to capitalize on recovery cycles at this specific ticker, suggests conviction in mean reversion, though the company's ongoing unprofitability and -0.4% annual revenue growth constrain the investment thesis.

Director Freedman buys 10,000 BLNE shares at $4.22; 5 of 5 prior buys at this ticker delivered 90d returns +409% to +417%.

Joseph David Freedman, a director, purchased 10,000 shares of Beeline Holdings at $4.22, increasing his holdings to 165,920 shares (+6.4% net change). This is a discretionary open-market buy of $42.2K. Notably, Freedman's prior trading pattern at BLNE shows a perfect 5-of-5 record: all five prior buys executed on 2025-06-17 delivered 90-day returns ranging from +409.0% to +416.7%, with 30-day returns between +110.4% and +113.6%. The current stock price of $3.79 is -60.1% from the 52-week high of $9.50, despite a 30-day surge of +139.9% and a 90-day surge of +180.7%. The company remains unprofitable (latest quarter net income: $-4.1M) with flat annual revenue growth (-0.4%), yet the director continues to accumulate despite recent share price weakness from the 52-week peak. His cross-ticker track record shows 15 prior buys with an 86.67% 90-day win rate and +239.7% average 90-day return, establishing a pattern of well-timed open-market purchases. This latest buy, placed after a recent sharp rally but from a depressed point in the 52-week range, extends his accumulation at a ticker where his historical timing has been exceptionally consistent.

Director Freedman sells 150,000 RCAT shares at $7.37 (now $6.79, -52.2% from 52w high)

Director Joseph David Freedman sold 150,000 shares (47.6% reduction in his pre-transaction holdings) at $7.37 on 2025-06-30, while the stock has since declined to $6.79 and sits 52.2% below its 52-week high of $14.19. Fundamentally, Red Cat Holdings reported net income of -$23,123,351 (negative) over its most recent full fiscal year despite revenue of $1,629,662 in the latest quarter and 80% annual revenue growth, signaling substantial unprofitability alongside top-line expansion. Freedman's cross-ticker track record shows 15 prior open-market buys with a 0.00% 90-day win rate and average 90-day returns of -73.7%, indicating a pattern of entries that systematically underperformed in the medium term, a context that frames this discretionary sale against a history of poorly-timed entries elsewhere.

Director Freedman buys 50,000 shares at $0.68 avg; stock down -42.4% in 30 days, -70.4% in 90 days.

Director Joseph David Freedman executed 10 separate purchases totaling 50,000 shares for $34,030.13 at a blended average price of $0.68, increasing his holdings by 47.2%. The purchase comes as BLNE trades at $0.72, down -42.4% over 30 days and -70.4% over 90 days from recent trading. Freedman's prior trades at BLNE show a 0% success rate at the 90-day mark, with his two most recent purchases (March 18–19, 2025) declining -59.5% and -76.6% respectively in 90 days, while his cross-ticker history shows an 0% win rate over 90 days with an average return of -73.7%. The company's fundamentals remain strained: latest quarterly revenue is $1.8M against a net loss of $6.8M, and the company has been unprofitable over its most recent full fiscal year. The recurring pattern of large purchases into sustained declines, combined with the company's unprofitable state and depressed valuation relative to the 52-week high of $9.50, suggests this purchase reflects the insider's continued exposure to a deteriorating investment rather than a positive conviction signal.

Director Joseph David Freedman buys 20,000 shares at avg $1.17 as BLNE stock plunges -87.9% from 52-week high, company unprofitable

Freedman purchased 20,000 shares across 3 separate transactions totaling $23,330.19, increasing his holdings from 85,910 to 105,910 shares. The timing is notable: the stock trades at $1.15, down -87.9% from its 52-week high of $9.50 and -60.3% over the past 30 days. Fundamentals remain challenged—the company posted $760.0K in revenue and net income of $-1.4M in the latest quarter, with full-year results unprofitable and annual revenue growth flat at -0.4%. Freedman's cross-ticker track record shows 2 prior open-market buys averaging -59.5% 30-day returns, and at this same ticker his prior buy on 2025-03-18 has returned -59.5% over 30 days; neither prior buy at BLNE has reached 90-day measurability yet. The purchase occurs amid severe stock depreciation and persistent operating losses, warranting investor scrutiny of the underlying business condition.

Director Freedman buys 8,250 shares (8.2K) at $2.75–$2.84 avg despite stock down 74.7% from 52-week high and company unprofitable.

Joseph David Freedman, a director, executed 2 separate purchases totaling 8,250 shares for $22,676.88 on March 18–19, 2025, increasing his holdings by 10.6% to 85,910 shares. This activity occurs against a deteriorating backdrop: the stock has declined 74.7% from its 52-week high of $9.50 to the current price of $2.40, and the company reported a net loss of $1,359,000 in its latest quarter on revenue of $760,000, with annual revenue shrinking 24.4% year-over-year. The director's accumulation at prices ($2.84 and $2.47) above the current market level, combined with the company's unprofitable state and severe stock decline, warrants examination of whether this reflects a conviction-driven thesis or other undisclosed factors driving the purchase decision.